PMID- 29403563
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220411
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 15
IP  - 2
DP  - 2018 Feb
TI  - High frequency and prognostic value of MYD88 L265P mutation in diffuse large 
      B-cell lymphoma with R-CHOP treatment.
PG  - 1707-1715
LID - 10.3892/ol.2017.7472 [doi]
AB  - The aim of this study was to analyze the prevalence and prognostic value of 
      myeloid differentiation factor 88 (MYD88) L265P in diffuse large B-cell lymphoma 
      (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, 
      vincristine, and prednisone (R-CHOP). We assessed the MYD88 L265P mutation using 
      an allele-specific semi-nested polymerase chain reaction method in 53 DLBCL 
      patients treated with R-CHOP. The MYD88 L265P mutation was detected in 16 of 53 
      DLBCL (30.19%) samples from patients treated with R-CHOP. Age and location were 
      statistically significantly associated with MYD88 L265P (P=0.025, 0.033, 
      respectively), while treatment response and tumor recurrence were not. Univariate 
      analysis showed that B symptoms (P=0.004) and Ki-67 (P=0.03) were significantly 
      associated with progression-free survival (PFS), while MYD88 L265P showed no 
      significant association with overall survival and PFS. Multivariate analysis 
      showed that B symptoms were significantly associated with PFS. Our study suggests 
      that the prognostic value of MYD88 L265P in DLBCL patients with R-CHOP requires 
      further research.
FAU - Yu, Sisi
AU  - Yu S
AD  - Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan 
      Cancer Center, School of Medicine, University of Electronic Science and 
      Technology of China, Chengdu, Sichuan 610051, P.R China.
FAU - Luo, Huaichao
AU  - Luo H
AD  - Department of Clinical Laboratory, Sichuan Cancer Hospital and Institute, Sichuan 
      Cancer Center, School of Medicine, University of Electronic Science and 
      Technology of China, Chengdu, Sichuan 610051, P.R China.
FAU - Pan, Meiling
AU  - Pan M
AD  - Department of Biostatistics, The University of Texas Health Science Center at 
      Houston, Houston, TX, USA.
FAU - Palomino, Luis Angel
AU  - Palomino LA
AD  - McGovern Medical School, The University of Texas Health Science Center at 
      Houston, Houston, TX, USA.
FAU - Song, Xiaoyu
AU  - Song X
AD  - Department of Clinical Laboratory, Sichuan Cancer Hospital and Institute, Sichuan 
      Cancer Center, School of Medicine, University of Electronic Science and 
      Technology of China, Chengdu, Sichuan 610051, P.R China.
FAU - Wu, Ping
AU  - Wu P
AD  - Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan 
      Cancer Center, School of Medicine, University of Electronic Science and 
      Technology of China, Chengdu, Sichuan 610051, P.R China.
FAU - Huang, Jian-Ming
AU  - Huang JM
AD  - Department of Biochemistry and Molecular Biology, Sichuan Cancer Hospital and 
      Institute, Sichuan Cancer Center, School of Medicine, University of Electronic 
      Science and Technology of China, Chengdu, Sichuan 610051, P.R. China.
FAU - Zhang, Zhihui
AU  - Zhang Z
AD  - Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan 
      Cancer Center, School of Medicine, University of Electronic Science and 
      Technology of China, Chengdu, Sichuan 610051, P.R China.
LA  - eng
PT  - Journal Article
DEP - 20171122
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC5780752
OTO - NOTNLM
OT  - allele-specific semi-nested polymerase chain reaction
OT  - and prednisone
OT  - diffuse large B-cell lymphoma
OT  - doxorubicin
OT  - myeloid differentiation factor 88 L265P
OT  - rituximab plus cyclophosphamide
OT  - vincristine
EDAT- 2018/02/07 06:00
MHDA- 2018/02/07 06:01
PMCR- 2017/11/22
CRDT- 2018/02/07 06:00
PHST- 2017/05/22 00:00 [received]
PHST- 2017/11/06 00:00 [accepted]
PHST- 2018/02/07 06:00 [entrez]
PHST- 2018/02/07 06:00 [pubmed]
PHST- 2018/02/07 06:01 [medline]
PHST- 2017/11/22 00:00 [pmc-release]
AID - OL-0-0-7472 [pii]
AID - 10.3892/ol.2017.7472 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Feb;15(2):1707-1715. doi: 10.3892/ol.2017.7472. Epub 2017 Nov 
      22.